FDA Accepts Topica’s Luliconazole IND to Begin Trials in Onychomycosis

TOPICA Pharmaceuticals, a privately-held biotechnology company, Monday announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis.
Fox Business